Recursion’s AI Drug Pipeline Progress Tests Investor Patience And Valuation

Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical data from its AI driven drug discovery programs.

Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 Results

In recent days, Recursion Pharmaceuticals reported positive early clinical data and advances in its AI-driven drug discovery pipeline, alongside a narrower-than-expected first-quarter EPS loss and ...
Business Wire

Dr. Imran S. Haque, Biology Machine Learning Expert, Joins Recursion as VP of Data Science

SALT LAKE CITY--(BUSINESS WIRE)--Imran S. Haque, Ph.D., a computer scientist by training, has made a name for himself at the intersection of machine learning and biology by maintaining a high standard ...
Forbes

What's Happening With RXRX Stock?

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
Business Wire

Recursion Announces Winners of RxRx1 Biology Machine Learning Competition

SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a tech-enabled biopharma company combining automated, experimental biology with artificial intelligence to discover novel treatments that extend beyond our ...
NJBIZ

Bayer, Recursion collaborate on digital drug discovery for fibrotic diseases

Bayer and digital biology company Recursion Inc. entered into a strategic collaboration agreement to leverage Recursion’s purpose-built, artificial intelligence-guided drug discovery platform and ...
Bloomberg L.P.

Roche Signs Machine-Learning Neuroscience Deal With Recursion

Roche Holding AG sealed a decade-long collaboration deal with U.S. biotech Recursion Pharmaceuticals Inc. to use machine learning to search out potential drugs for neuroscience and cancer. The deal ...